Longitudinal association of 25-Hydroxyvitamin D with adipokines and markers of glucose metabolism among Brazilian pregnant women by Benaim, Camila et al.
1 
 
Longitudinal Association of 25-Hydroxyvitamin D with Adipokines and Markers 
of Glucose Metabolism among Brazilian Pregnant Women 
Camila Benaim1,2 – camilabenaimnutri@gmail.com 
Paula Guedes Cocate1,2 - paulacocate@gmail.com 
Erica Guimarães de Barros1 - ericagbarros86@gmail.com 
Nadya Helena Alves-Santos1,2 - nadyahasantos@gmail.com 
Amanda Caroline Cunha Figueiredo1,2 - amandacfg@gmail.com 
Ana Beatriz Franco-Sena1,3 - nutrianabeatriz@gmail.com 
Jaqueline Lepsch 1,4 - jaquelepsch@gmail.com 
Amanda Rodrigues Amorim Adegboye5 - A.Adegboye@gre.ac.uk 
Rana Mokhtar6 - rmokhtar@gmail.com 
Michael F. Holick6 - mfholick@bu.edu 
Gilberto Kac*1,2 - gilberto.kac@gmail.com 
 
1 Nutritional Epidemiology Observatory, Department of Social and Applied Nutrition, 
Institute of Nutrition Josué de Castro, Rio de Janeiro Federal University, RJ, 21941-
590, Brazil. 
2 Postgraduate Program in Nutrition, Institute of Nutrition Josué de Castro, Rio de 
Janeiro Federal University, RJ, 21941-590, Brazil. 
3 Department of Social Nutrition, Emília de Jesus Ferreiro Nutrition School, Fluminense 
Federal University, Niteroi, 24020-140, Brazil. 
4 Faculty of Nutrition, Santa Ursula University, RJ, 22231-040, Brazil. 
5 Faculty of Education and Health, Department of Psychology, Social Work and 
Counselling, University of Greenwich, SE9 2UG, London. 
6 Section of Endocrinology, Diabetes & Nutrition, Department of Medicine, Boston 
University School of Medicine (BUSM), Boston, MA, 02118, United States of 
America. 
 
Institute of Nutrition Josué de Castro, Rio de Janeiro Federal University 
Avenida Carlos Chagas Filho, 373, CCS, Bloco J, 2º andar  
Cidade Universitária – Ilha do Fundão; CEP: 21941-902, Rio de Janeiro – RJ, Brasil 
Phone: (+55) 21 39386595 / Fax: (+55) 21 22808343 
*Author to correspondence  
 
2 
 
Short title: Vitamin D and biomarkers in pregnancy 
Keywords: Adipokines, biomarkers, glycaemia, pregnancy, vitamin D  
 
Abstract 
 
This study aimed to evaluate the longitudinal association of vitamin D status with 
glycaemia, insulin, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), 
adiponectin and leptin. A prospective cohort with 181 healthy, pregnant Brazilian 
women was followed at the 5th–13th, 20th–26th, and 30th–36th gestational weeks. In this 
cohort, 25(OH)D plasma concentrations were analysed using liquid chromatography-
tandem mass spectrometry. Vitamin D status was categorized as sufficient or 
insufficient using the Endocrine Society Practice Guidelines (ES) (≥75/<75 nmol/L) and 
the Institute of Medicine (IOM) (≥50/<50 nmol/L) thresholds. Linear mixed-effect 
regression models were employed to evaluate the association between vitamin D status 
and each outcome, considering the interaction terms between vitamin D status and 
gestational age (P<0.1). At baseline, 70.7% of pregnant women had 25(OH)D levels 
<75 nmol/L and 16% had levels <50 nmol/L. Women with sufficient vitamin D status at 
baseline, using both the ES and IOM thresholds, presented lower glycaemia than those 
with insufficient 25(OH)D. Pregnant women with 25(OH)D concentrations <75 nmol/L 
showed lower insulin (β=-0.12; 95% CI -0.251, 0.009; P=0.069) and adiponectin (β=-
0.070; 95% CI -0.150, 0.010; P=0.085) concentrations throughout pregnancy than those 
with 25(OH)D levels ≥75 nmol/L. Pregnant women with 25(OH)D <50 nmol/L at 
baseline presented significantly higher leptin concentrations than those with 25(OH)D 
levels ≥50 nmol/L (β=-0.253, 95% CI: -0.044; 0.550, P=0.095). The baseline status of 
vitamin D influences the biomarkers involved in glucose metabolism. Vitamin D 
sufficient women at baseline had higher increases of insulin and adiponectin changes 
throughout gestation than those who were insufficient.  
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Introduction 
Prevention of gestational diabetes mellitus (GDM) is a key intervention to 
circumvent the maternal and foetal consequences of this disease. The primary method of 
preventing GDM is by lifestyle changes, such as physical activity and diet(1). One 
important modifiable risk factor is vitamin D deficiency among pregnant women. 
Vitamin D deficiency is considered highly prevalent worldwide and often persists 
during pregnancy(2,3). Studies have suggested that low concentrations of vitamin D may 
be associated with alterations in glucose metabolism(4), can be a risk factor for GDM(5-7) 
and are characterized by glucose intolerance or glycaemia values higher than the normal 
range when detected during pregnancy(8).  
One possible mechanism by which vitamin D may act on glucose metabolism is 
by increasing adiponectin secretion(9,10). This adipokine has insulin sensitization 
properties of the target cells (liver, skeletal muscle and adipose tissue) and can enhance 
glucose uptake in muscle tissue(11-13). Adiponectin also protects β-cells from immune 
attack and reduces insulin resistance through immunoregulatory and anti-inflammatory 
effects(11-14). In pregnant women, adiponectin concentrations have been inversely 
associated with adverse maternal outcomes, such as GDM(15,16), overweight, and 
obesity(17). During pregnancy, a reduction in maternal plasma adiponectin 
concentrations is expected(18,19). Many factors can influence the expression of this 
adipokine. Vitamin D concentration is one example(13,20), as it down-regulates pro-
inflammatory cytokines and up-regulates anti-inflammatory cytokines. Vitamin D 
appears to be positively associated with adiponectin gene expression, and suppresses the 
renin-angiotensin-aldosterone system (RAS) components secreted by adipocytes, thus 
contributing to increased adiponectin secretion(20-22). Low 25(OH)D concentrations may 
then reduce the secretion of adiponectin and could be considered a risk factor for GDM 
and insulin resistance(13,23,24).  
 Leptin is a hormone that regulates lipid metabolism and inflammation by 
influencing glucose metabolism in an inverse manner to adiponectin, i.e., it reduces 
insulin sensitivity(25). Leptin is directly associated with preeclampsia, GDM and 
macrosomia(26,27). Studies have shown an inverse association between vitamin D and 
leptin concentrations(28-30). The mechanism by which vitamin D metabolites impact 
leptin levels remains unclear. One possible mechanism is that the fat solubility of 
vitamin D can cause it to be sequestered in fat tissues, leading to a high level of 
intracellular calcium, which increases lipogenesis and decreases lipolysis(31). A lower 
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serum vitamin D may lead to a higher serum leptin since its concentration is related to 
greater body fat mass(32,33). However, randomized clinical trials have found no 
association between vitamin D supplementation and changes in leptin 
concentrations(31,34).  
  There are few studies evaluating the association between vitamin D status, 
glycaemia and adipokines during pregnancy, particularly among healthy pregnant 
women without comorbidities such as GDM(31,35,36). The aim of this study was to 
evaluate the vitamin D status of pregnant women in the first trimester and, if variation 
in vitamin D status during pregnancy was associated with changes in adiponectin, leptin 
and glycaemia concentrations throughout pregnancy among a cohort of healthy 
Brazilian women. 
 
Methods 
Study design 
This study consists of a prospective cohort with healthy pregnant adult women 
from a public health care centre in Rio de Janeiro, Brazil, carried out from November 
2009 to October 2011. 
 Two hundred and ninety-nine women were invited to participate in the study in 
accordance with the following eligibility criteria: (a) being between 5-13 weeks of 
gestation, (b) aged between 20 and 40 years, and (c) without any known infectious or 
chronic non-communicable diseases (except obesity). Criteria for exclusions after 
baseline clinical evaluation consisted of the following: miscarriages (n=25), chronic 
arterial hypertension (n=3), multiple gestation (n=4), diagnosis of infectious or non-
communicable disease after starting the study (n=11), advanced pregnancy (≥14 weeks 
of gestation, n=15), prenatal care withdrawn (n=7), stillbirth (n=5), no vitamin D 
measured at baseline (n=30), self-reported glycaemia alteration (n=12), and no 
biochemical analyses performed (n=1). 
 
Biochemical analyses 
 Venous blood samples were taken after a 12 h overnight fasting at three different 
visits (first, second, and third gestational trimesters). Samples were immediately 
centrifuged (5,000 rpm for 5 minutes), aliquoted and stored at -80oC until further 
analysis. Plasma samples were used to determine 25-hydroxyvitamin D [25(OH)D] 
(nmol/L),  leptin (ng/dL) and adiponectin (ng/mL) concentrations.  
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Main independent variable 
Plasma 25(OH)D concentrations were analysed using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) at the Quest Diagnostics Nichols Institute 
laboratory (San Juan Capistrano, CA, USA) using the LC Thermo Cohesive System 
coupled to a Thermo Quantum Ultra Mass Spectrometer (Thermo Fisher; San Jose, CA, 
USA). This method is the gold standard with analytical measurement range of 10-640 
nmol/L and the coefficient of variation <10%.  
The 25(OH)D concentrations at baseline (5th–13th gestational weeks) were used 
to determine vitamin D status. Pregnant women were categorized as being vitamin D 
sufficient or insufficient, using two cut-points based on the Endocrine Society Practice 
Guidelines (ES) and the Institute of Medicine (IOM). According to the ES, vitamin D 
sufficiency and insufficiency are defined as having 25(OH)D concentrations ≥75 
nmol/L and <75 nmol/L, respectively(2). Using the IOM cut-points, sufficiency and 
insufficiency were defined as 25(OH)D concentrations ≥50 nmol/L or <50 nmol/L, 
respectively(37). There are controversies in the literature, as to which cut-point of 
vitamin D for insufficiency is the most appropriate. There is also no specific guideline 
set forth for pregnant women. We have decided to report both cut-points, to increase 
transparency and to allow for comparability between various studies in the literature.   
 
Dependent variables  
Serum fasting glycaemia was estimated by enzymatic colorimetric methods, 
using commercial kits (Linco Research, St. Charles, Missouri, USA and Wiener Lab., 
Rosario, Argentina, respectively) and insulin concentrations were assessed by enzyme-
linked immunosorbent assay (ELISA) using specific commercial kits designed for 
humans (Millipore, St. Charles, MO, USA), with sensitivity of 2 μU/ml. HOMA-IR was 
calculated based on the product of fasting insulin (U/mL) and glucose (mmol/L) 
divided by 22.5(38). The adipokines were evaluated using ELISA, with sensitivities of 
0.78 ng/mL for adiponectin and 0.5 ng/dL for leptin.  
 
Covariate assessment 
 A structured questionnaire administered at baseline was used to collect 
information on study population characteristics including: age (y), per-capita monthly 
household income (USD), parity (nulliparous or primiparous/multiparous) and self-
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reported skin colour (white, black or mixed). Date of first blood collection was used to 
define the season at baseline (summer, autumn, winter and spring). 
Anthropometric measurements were collected according to standardized 
procedures at baseline(39). Weight was measured using a digital scale (Filizzola PL 150, 
Filizzola Ltda., São Paulo, Brazil) at each gestational trimester and height was measured 
in duplicate using a portable stadiometer (Seca Ltda., Hamburg, Germany). The early 
pregnancy Body Mass Index (BMI) was calculated using the formula: weight at 
baseline (kg)/height2 (m2). The gestational age was obtained from the first 
ultrasonography (USG) exam (92.3%; n = 167) or using the reported date of the last 
menstrual period if the USG was not performed before the 24th week of gestation (7.7%; 
n = 14). 
The total dietary vitamin D intake (IU/day) was calculated using Nutritional 
Composition Tables from the Brazilian Institute of Geography and Statistics(40) 
according to a semi-quantitative food frequency questionnaire (FFQ)(41). The FFQ was 
validated for the adult population of Rio de Janeiro(41), and administered in the first 
trimester of gestation by trained interviewers and referring to intake of the last six 
months. Data on vitamin D supplementation was self-reported throughout pregnancy 
(first, second and third trimesters).  
 
Statistical analysis 
 Data distribution was analysed according to the Shapiro-Wilk test. Maternal age, 
vitamin D intake, per-capita family income, early pregnancy BMI, glycaemia, insulin, 
HOMA-IR, adiponectin and leptin were not normally distributed (Shapiro-Wilk test p-
value <0.05). The sample characteristics are described using medians and interquartile 
ranges (IQR). Categorical data are presented as absolute values (n) and relative 
frequencies (%). Baseline characteristics were stratified according to vitamin D status 
(sufficiency v. insufficiency). To compare medians and frequencies, the Mann-Whitney 
U test and the chi-squared test were used, respectively.  
 Dropout analyses were performed to verify the presence of selection bias 
comparing those who completed the study to those who were lost to follow-up. The 
following variables were considered: vitamin D status according to thresholds, dietary 
vitamin D intake, age, early pregnancy BMI, per-capita family income, glycaemia, 
insulin, HOMA-IR, adiponectin and leptin concentrations, parity, self-reported skin 
colour and season at recruitment. 
 7 
 
Scatter plots containing longitudinal prediction, and 95% confidence intervals 
(CIs) were constructed to illustrate the variation in glycaemia and adipokine 
concentrations during pregnancy according to vitamin D baseline status.  
Linear mixed effect (LME) models were performed in order to assess the 
longitudinal associations of vitamin D baseline status with the outcomes throughout 
pregnancy. The modelling process allows the inclusion of time-dependent and time-
independent variables, it is robust to deal with unbalanced time intervals, and 
considers the correlation between repeated measures(42,43). Interactions between 
vitamin D baseline status and gestational age were considered to explore the 
longitudinal behaviour of the evaluated outcomes. The LME models were adjusted 
for confounders selected by biological plausibility and statistical significance (p <0.2) 
in the bivariate analysis for each of the five outcomes (glycaemia, insulin, HOMA-IR, 
adiponectin and leptin). The test to detect interactions was low powered. We 
considered P <0.1(44) as a threshold to define statistically significance for the 
interaction terms and P <0.05 for the main effect variables.  
All analyses were performed in Stata 12.0 (Stata Corporation, College station, 
TX). The significant interactions identified in the LME models were illustrated by 
graphs plotted with RStudio 3.3.1 software(45). 
 
Ethical approval 
This study was conducted according to the guidelines of the Declaration of 
Helsinki. The Rio de Janeiro Federal University Maternity Hospital Ethics Committee 
(Protocol number: 0023.0.361.000-08), and the Municipal Secretary of Rio de Janeiro 
Ethics Committee (Protocol number: 0139.0.314.000-09) approved all procedures 
involving human subjects. All participants signed an informed consent about 
participation in the study.  
 
Results 
The baseline sample comprised of 181 pregnant women. From baseline to the 
second trimester follow-up, eleven women moved out from the prenatal program, two 
withdrew consent, four abandoned prenatal care at the study site, twelve missed the 
follow-up interview and one had no biochemical analyses performed, leaving a sample 
of 151 women at the second trimester. From the second to the third visit, six women 
were classified as lost to follow-up and seven had no biochemical analyses performed. 
 8 
 
Eleven women missed the second trimester interview, but returned to the study in the 
third trimester. Therefore, our final sample at the third trimester comprised 149 women 
(Supplemental figure 1). 
 In total, 149 women completed the study and 32 were lost to follow-up. There 
were no significant differences between women who completed the study compared to 
those who were lost during follow-up (Supplemental table 1). 
 At baseline, women had a median age of 26 y (22.0-31.0), early pregnancy BMI 
of 23.7 kg/m² (21.9-27.0), per-capita family income of 292.4 USD (184.8-421.0) and 
reported a vitamin D intake of 134.2 IU/day (84.2-185.4), and 46.9% self-reported their 
skin colour to be mixed. The prevalence of vitamin D insufficiency was 70.7% 
(n=128/181) according to cut-offs set by ES and 16.0% (n=29/181) according the cut-
offs proposed by the IOM. Women who began the study in the winter, compared to the 
summer, were more likely to be vitamin D insufficient (ES: 33.6% v. 15.6%, 
respectively, P <0.001; IOM: 51.7% v. 3.5%, respectively, P <0.001) (Table 1). None of 
the women who participated in the study received nutritional vitamin D 
supplementation (data not shown). 
 Pregnant women with vitamin D sufficiency at baseline showed lower glycaemia 
when compared with insufficient women (ES: median 79.5 v. 84.0 mg/L, respectively, 
P=0.003; IOM: median 83.0 v. 84.0 mg/L, respectively, P=0.034) (Table 2). The 
glycaemia decreased from the first to the second trimester, followed by a slight increase 
from the second to the third trimester onwards, in both women with vitamin D 
sufficiency and insufficiency at baseline (Fig. 1A and 1B). However, the rate of change 
throughout pregnancy for glycaemia did not show a significant difference between the 
baseline vitamin D groups (Table 3). Similar results were observed when 25(OH)D 
throughout pregnancy was analysed (Fig. 2A; 2B and Table 4). 
 The rate of change of insulin was greater among vitamin D sufficient women at 
baseline (ES: β=0.166; 95% CI 0.047, 0.285; P=0.006; IOM: β=0.091; 95% CI 0.019, 
0.162; P=0.013) (Fig. 1C and 1D). There was a less-pronounced increase of insulin 
throughout pregnancy among vitamin D insufficient women compared to those who 
started with sufficient status according to ES (interaction β=-0.12; 95% CI -0.251, 
0.009; P=0.069) (Table 3). We found significant results when 25(OH)D throughout 
pregnancy was analysed using the IOM thresholds (interaction β=-0.153; 95% CI -
0.325, 0.018, P=0.080) (Fig. 2C and 2D and Table 4). 
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 There was a tendency of lower HOMA-IR in the group of women classified as 
sufficient vitamin D status at baseline when compared with those with vitamin D 
insufficient status (ES: median 0.65 v. 0.93, respectively, P=0.062; IOM: median 0.82 v. 
1.14, respectively, P=0.071) (Table 2). HOMA-IR increased throughout gestation 
among women with sufficient vitamin D status at baseline (ES: β=0.019; 95% CI 
0.00001, 0.039; P=0.050) but did not change in the insufficient group (Fig. 1E and 1F). 
However, the results were not significant for this biomarker when baseline vitamin D- 
sufficient and insufficient women were compared (Table 3). We found significant 
results when 25(OH)D was analysed throughout pregnancy using the IOM thresholds 
(interaction β=-0.030; 95% CI -0.065, 0.005; P=0.094) (Fig. 2E; 2F and Table 4). 
 The trend in changes in adiponectin throughout pregnancy showed an increase 
from the beginning of pregnancy until the second trimester and was followed by a slight 
decrease at the end of gestation for both vitamin D status groups, whether measured at 
baseline or when 25(OH)D varied throughout pregnancy (Fig. 1G; 1H; 2G; 2H). 
Women with vitamin D insufficient status at baseline started gestation with higher 
median plasma levels of adiponectin, although this association was not significant (5.26 
µg/ml v. 4.49 µg/ml, P=0.170) (Table 2). However, the adiponectin rate of change 
throughout pregnancy was significantly higher in women with sufficient vitamin D 
levels at baseline (ES: β=-0.070; 95% CI -0.150, 0.010; P=0.085) (Table 3). The 
women with sufficient vitamin D status at baseline, according to IOM classification, 
tended to have a lower rate of change of adiponectin throughout pregnancy, although 
this did not reach significance (Table 3; Fig. 1H). The adiponectin rate of change 
throughout pregnancy was significantly higher in women with sufficient vitamin D 
levels when this marker varied throughout pregnancy (ES: β=-0.056; 95% CI -0.116, 
0.004; P=0.066) (Table 4). 
 There were no significant differences in leptin concentrations, comparing each 
trimester individually, according to ES, but it was found that women with inadequate 
vitamin D status according to IOM presented higher leptin concentrations (Table 2). 
Women with insufficient vitamin D status according to ES had a significant decrease in 
leptin concentrations (β=-0.026; 95% CI -0.042, -0.009; P=0.002). Using the IOM cut-
points, the decrease was significant only within the sufficient group (β=-0.021; 95% CI 
-0.036, -0.007; P=0.004) (Fig. 1I and 1J). Women with insufficient vitamin D levels 
presented a greater increase in leptin concentrations, in relation to the sufficient group, 
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according to IOM (β=-0.253; 95% CI -0.044, 0.550; P=0.095) (Table 3). These results 
did not hold when 25(OH)D varied throughout pregnancy (Fig. 2I; 2J; Table 4). 
 
Discussion 
The main result of this study is the difference in the variation of adiponectin and 
insulin concentrations throughout pregnancy according to vitamin D baseline status 
defined by the ES Guidelines. We observed that throughout pregnancy the rate of 
increase for both biomarkers was greater among women with vitamin D sufficiency 
compared with women who started their pregnancy in a vitamin D deficient state. 
Another important finding is that women with insufficient vitamin D at baseline had a 
higher increase in leptin levels during gestation compared to the sufficient group 
according to the IOM classification. Additionally, women classified with vitamin D 
sufficiency, independently of the cut-off criteria, had lower baseline glycaemia, 
although the rate of change of this biomarker did not differ between the two vitamin D 
status groups. 
The definition of vitamin D sufficiency or insufficiency remains controversial. 
Currently, there are no specific cut-points for pregnant women, and the same cut-points 
are used for adults. It is well known that the thresholds for several biomarkers are rarely 
available for this period of life and the case is not different for vitamin D. Thus, more 
research is needed to establish the adequate cut-off point for this unique period in 
women’s life. In the current study we opted to use two different thresholds presented by 
the two governing bodies of vitamin D status: the ES and the IOM. This strategy allows 
comparability with other studies in the literature and provides a broader picture of the 
studied associations in place. Another aspect of studies conducted during pregnancy that 
can be misleading is related to the timing vitamin D is assessed during pregnancy. The 
conclusions may vary if studies consider only baseline vitamin D, e.g. first trimester, 
what should be a representation of how preconception period affects the parameters 
evaluated throughout pregnancy. On the other end, if data is available, for several time 
points this can provides a clearer picture of the trajectory and how this may influence a 
specific outcome. In general, the directions of the rate of change trajectories for the 
studied outcomes were similar regardless of the 25(OH)D threshold used. Adiponectin 
was the exception. Pregnant women with sufficient vitamin D levels at baseline showed 
significantly higher levels of adiponectin when the ES criteria was used, while 
according to the IOM classification, they showed lower levels, but the results were not 
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significant. The results regarding the timing of vitamin D assessment yield slight 
conflicting results for insulin, HOMA-IR and leptin. Again, the direction of the 
associations remained the same, but the statistical significance of the interaction 
changed depending on the timing and threshold used. An important finding of this study 
is that differing conclusions can be made depending on the vitamin D deficiency 
threshold used or the timing when vitamin D status is evaluated. This is of particular 
importance when considering the conflicting results in the scientific literature. 
The longitudinal data with three time points are an important strength of this 
study. We did not identify other studies assessing these associations with longitudinal 
data in the scientific literature. Moreover, the robust statistical analysis of the present 
study, taking into account the correlations between repeated measures and considering 
all women had information on at least two time points, is an additional strength. The 
method used to measure plasma 25(OH)D concentrations was LC-MS/MS, which is 
considered the gold standard for this marker. Furthermore, we also evaluated dietary 
vitamin D intake and supplementation. However, limitations, such as losses to follow-
up, and the absence of information about sun exposure data, should be acknowledged. 
To assess whether the losses to follow-up biased our results we examined whether those 
women who were lost to follow-up differed from those who remained in the study. This 
analysis shows no significant differences in those who were lost to follow-up, which 
suggests that losses to follow-up occurred randomly in this study. We also adjusted all 
models for the season of the year at the time of blood collection, which was used as a 
proxy for sun exposure, since these data were not available. Additionally, we did not 
measure the expression of enzymes that are involved in the conversion of vitamin D and 
the vitamin D receptor (VDR) in the placenta to support extra-renal synthesis of 
1,25(OH)2D3 during pregnancy
(46). This could influence the outcomes; however, the 
maternal kidneys are likely to be the major source of increased maternal serum 
1,25(OH)2D3 during pregnancy
(46). 
A high prevalence of vitamin D insufficiency according to the ES was 
previously reported in this cohort(47), which is similar to results found for pregnant 
women in other studies using this threshold(48, 49). Schneuer et al. (2014) observed that 
80.4% of 5,109 pregnant women from Australia had vitamin D insufficiency in the first 
trimester. Flood-Nichols et al. (2015) found that 70% of 235 American women had 
vitamin D insufficiency in early pregnancy, while 59.0% of 190 Brazilian pregnant 
women presented vitamin D insufficiency(50). We identified a low intake of vitamin D 
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during pregnancy (134.2 IU/day) in the present study by considering either the 
recommendation of the ES of 1500-2000 IU/day or the Brazilian recommendations (600 
IU/day)(51). We also observed that none of the women used vitamin D supplements, 
since this is not part of public prenatal care. In Brazil, only supplementation with iron 
(40 mg) and folic acid (400 mcg) are mandatory for pregnant women(52). Despite low 
vitamin D dietary intake, we have previously reported a longitudinal increase in 
25(OH)D levels throughout pregnancy in this cohort of women(47). Additionally, the 
level of increase in 25(OH)D concentrations depended on seasonal variation. Pregnant 
women who started their pregnancy during the winter, spring or autumn seasons had a 
significant longitudinal increase in 25(OH)D concentrations, while women who began 
pregnancy during the summer season showed no significant changes in 25(OH)D 
concentrations throughout pregnancy(47). 
In the current cohort, pregnant women with vitamin D insufficiency according to 
the ES had higher glycaemia in the first trimester compared to women with vitamin D 
sufficiency. This result corroborates findings from an earlier cross-sectional study with 
155 Iranian pregnant women. That study showed a significant inverse association 
between first trimester 25(OH)D concentrations and fasting glucose (r=0.238; P 
=0.003)(53). On another cross-sectional study, Casey et al. (2018) evaluated the 
association between vitamin D and glycaemia markers at the third gestation trimester 
and found no significant association with fasting glucose or HOMA-IR(54). These results 
are in line with the present findings regarding the third trimester. It seems that the 
relationship between vitamin D and glucose concentrations may be mediated by the role 
of vitamin D on insulin action. 
Due to increased maternal adiposity and placental production, increased insulin 
resistance is expected to occur during pregnancy from the 18th gestational week until the 
third trimester(55). Peripheral insulin sensitivity decreases in the third trimester, and the 
hepatic glucose production increases compared to the beginning of pregnancy(56). 
Vitamin D appears to play a role in insulin sensitivity, stimulating the expression of the 
insulin receptors and improving glycaemic metabolism(57-59). Thus, glucose would be 
better absorbed by the cells and the glycaemia would be at lower levels. 
The longitudinal analyses from the present study show that pregnant women 
with vitamin D sufficiency at baseline had sharper increases in insulin concentration 
compared to those with vitamin D insufficiency according to both thresholds used. The 
greater increase of insulin in the group with vitamin D adequacy was not followed by 
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significant longitudinal increases in glycaemia or HOMA-IR during pregnancy. The 
active metabolite of vitamin D [1,25(OH)2D3] has been shown to be involved in insulin 
secretion by the pancreas and glucose homeostasis(14). Additionally, pancreatic β-cells 
are known to have vitamin D receptors and an insulin gene promoter that is stimulated 
by 1,25(OH)2D3, thus indicating a direct association between vitamin D and insulin
(60). 
This mechanism could explain the greater insulin increase among women with vitamin 
D adequacy compared to those with vitamin D inadequacy in our sample. This result 
reinforces a small study performed with adults that found that subjects with vitamin D 
deficiency (<50 nmol/mL) secrete less insulin than subjects with adequacy status(61). 
A recent experimental study investigated the metabolic effects of adiponectin on 
maternal glucose and lipid metabolism by comparing pregnant rats with and without 
adiponectin deficiency(62,63). The authors observed that adiponectin stimulated the β cell 
proliferation and impaired the islet mass without differences in insulin sensitivity effects 
in comparison to the deficient group(4,62,63). This finding allows suggesting another 
mechanism on insulin besides the well-established insulin-sensitizing property of this 
adipokine(62,63). In humans, pregnant women present this phenomenon of β cell 
proliferation without increase in islet mass, but this particular study was limited because 
it was conducted in women who died during pregnancy(64). However, it is possible that 
adiponectin also exerts an effect on human cell proliferation(62). Vitamin D could 
stimulate the adiponectin secretion, which in turn, stimulates beta-cell proliferation, 
increasing insulin secretion. This explanation would support our results of greater 
increases in adiponectin and insulin in pregnant women with vitamin D adequacy status 
during pregnancy.   
We found an association between vitamin D status and the rate of change in 
adiponectin during pregnancy. In the present study, pregnant women with adequate 
levels of 25(OH)D in the first trimester showed a sharper increase in adiponectin 
concentration throughout pregnancy when compared to women with inadequate levels 
of vitamin D. Additionally, 1,25(OH)2D is known to regulate the renin-angiotensin 
system (RAS) in a negative feedback loop by binding with a transcription factor 
necessary for the expression of renin(65). Inhibition of RAS results in increased levels of 
adiponectin and improved insulin sensitivity, which exerts influence on glycaemia(20). 
This mechanism of action can explain our result of higher increase of adiponectin 
among pregnant women with adequate 25(OH)D levels compared to those with 
inadequate levels.  
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Previous studies found direct associations between vitamin D and adiponectin 
independently of BMI in both young and adult populations(66-68), but no studies were 
found with pregnant women.  
No differences were observed in mean adiponectin and leptin concentrations 
between pregnant women with vitamin D adequacy or inadequacy at each gestational 
trimester, i.e., cross-sectional analysis. Similarly, a case-control study conducted by 
McManus et al. (2014)(69) also found no correlation between 25(OH)D and adipokine 
concentrations during the third trimester in both healthy pregnant women and pregnant 
women with GDM.  
A meta-analysis conducted in 2016 showed that vitamin D supplementation 
increased the serum leptin concentrations although a meta-analysis using cross-sectional 
studies with non-pregnant subjects found inverse associations between 25(OH)D and 
leptin levels (Fisher's Z=-0.93; 95% CI: -0.95, -0.91)(31). In the present cohort, it was 
observed that pregnant women with vitamin D sufficiency showed a less pronounced 
increase in leptin until the second trimester and a higher decrease until the end of 
gestation, although this did not reach significance. Similarly, Walsh et al. (2013) 
evaluated the correlation between 25(OH)D and leptin levels at early pregnancy and 28 
weeks of gestation and found a negative association that was not significant(70).  
 
Conclusion 
 Pregnant Brazilian women with vitamin D adequacy [25(OH)D ≥75 nmol/L] at 
the first trimester had a higher rate of increase in adiponectin and insulin concentrations 
throughout pregnancy compared to women with vitamin D inadequacy [25(OH)D <75 
nmol/L]. These results indicate that vitamin D status at the beginning of gestation may 
influence the changes in adiponectin and insulin during pregnancy. Although these 
women had higher values of insulin, there were no higher glycaemia values, showing 
that there was an adequate metabolic response. This result reinforces the importance of 
monitoring the vitamin D status of pregnant women in the first trimester of pregnancy 
in order to achieve a favourable metabolic profile for reducing the risk of undesired 
pregnancy outcomes. Given the scarcity of studies, there is a need for research 
involving pregnant women to evaluate this relationship and to provide further evidence 
on this topic. 
 
 
 15 
 
Acknowledgment  
The authors are grateful to all participants of the cohort study, to the Municipal 
Health Centre Heitor Beltrão for giving us the space and allow the completion of data 
collection; to the Quest Diagnostics Nichols Institute laboratory (San Juan Capistrano, 
CA, USA) for performing the analyses of vitamin D. Additionally, to the National 
Council for Scientific and Technological Development (CNPq in the Portuguese 
acronym; grant number: 471196/2010-0) and the Carlos Chagas Filho Foundation for 
Research Support of Rio de Janeiro State (FAPERJ in the Portuguese acronym, grant 
number E-26/111.400/2010, E_14/2010) for the to financial support. FAPERJ and 
CNPq had no role in the design, analysis or writing of this article.  
 
The authors declare no conflict of interest.  
Benaim C, Cocate P, Kac G formulated the research question, designed the study 
and developed the protocol. Benaim C and Cocate P conducted the statistical analysis, 
and Alves-Santos NH provided support for statistical analysis. Barros E, Franco-Sena 
AB, Figueiredo A, Lepsch J, Adegboye AA, Holick M and Mokhtar R assisted with the 
literature searches and with the writing of the manuscript. All authors substantially have 
contributed to and have approved the final version of this manuscript.  
 
References 
1. Donazar-Ezcurra M, López-Del Burgo C, Bes-Rastrollo M (2017). Primary 
prevention of gestational diabetes mellitus through nutritional factors: a systematic 
review. BMC Pregnancy Childbirth 17, 30. 
2. Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011). Evaluation, treatment, and 
prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J 
Clin Endocrinol Metab 96, 1911-30. 
3. Wei SQ, Qi HP, Luo ZC et al (2013). Maternal vitamin D status and adverse 
pregnancy outcomes: a systematic review and meta-analysis. Journal of Maternal Fetal 
Neonatal Medicine 26:889-99. 
4. Amegah AK, Klevor MK, Wagner CL (2017). Maternal vitamin D insufficiency and 
risk of adverse pregnancy and birth outcomes: A systematic review and meta-analysis of 
longitudinal studies. PLoS One 12:e0173605.  
 16 
 
5. Lau SL, Gunton JE, Athayde NP et al (2011). Serum 25-hydroxyvitamin D and 
glycated haemoglobin levels in women with gestational diabetes mellitus. Med J Aust, 
194334-7. 
6. Loy SL, Lek N, Yap F et al (2015). Association of Maternal Vitamin D Status with 
Glucose Tolerance and Caesarean Section in a Multi-Ethnic Asian Cohort: The 
Growing Up in Singapore Towards Healthy Outcomes Study. PLoS One 10,e0142239. 
7. Bener A, Al-Hamaq AO, Saleh NM (2013). Association between vitamin D 
insufficiency and adverse pregnancy outcome: global comparisons. Int J Womens 
Health 5,523-31. 
8. Organization WH (2013). Diagnostic criteria and classification of hyperglycaemia 
first detected in pregnancy. Geneva: WHO. 
9. Dinca M, Serban MC, Sahebkar A  et al (2016). Does vitamin D supplementation 
alter plasma adipokines concentrations? A systematic review and meta-analysis of 
randomized controlled trials. Pharmacol Res 107, 360-71. 
10. Karras SN, Polyzos SA, Newton DA et al (2018). Adiponectin and vitamin D-
binding protein are independently associated at birth in both mothers and neonates. 
Endocrine 59, 164-74. 
11. Rosen ED, Spiegelman BM (2006). Adipocytes as regulators of energy balance and 
glucose homeostasis. Nature 444,847-53. 
12. Lara-Castro C, Fu Y, Chung BH et al (2007). Adiponectin and the metabolic 
syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr 
Opin Lipidol 18, 263-70. 
13. Rühl R, Landrier JF (2016). Dietary regulation of adiponectin by direct and indirect 
lipid activators of nuclear hormone receptors. Mol Nutr Food Res 60, 175-84. 
14. Sung CC, Liao MT, Lu KC et al (2012). Role of vitamin D in insulin resistance. J 
Biomed Biotechnol 2012, 634195. 
15. Xu J, Zhao YH, Chen YP et al (2014). Maternal circulating concentrations of tumor 
necrosis factor-alpha, leptin, and adiponectin in gestational diabetes mellitus: a 
systematic review and meta-analysis. ScientificWorldJournal. 201, 926932. 
16. Retnakaran A, Retnakaran R (2012). Adiponectin in pregnancy: implications for 
health and disease. Curr Med Chem 19, 5444-50. 
17. Ianniello F, Quagliozzi L, Caruso A et al (2013). Low adiponectin in 
overweight/obese women: association with diabetes during pregnancy. Eur Rev Med 
Pharmacol Sci 17, 3197-205. 
 17 
 
18. Mazaki-Tovi S, Romero R, Kusanovic JP et al (2008). Adiponectin multimers in 
maternal plasma. J Matern Fetal Neonatal Med 21,796-815. 
19. Nien JK, Mazaki-Tovi S, Romero R et al (2007). Plasma adiponectin concentrations 
in non-pregnant, normal and overweight pregnant women. J Perinat Med 35, 522-31. 
20. Vaidya A, Forman JP, Underwood PC et al (2011). The influence of body mass 
index and renin-angiotensin-aldosterone system activity on the relationship between 25-
hydroxyvitamin D and adiponectin in Caucasian men. Eur J Endocrinol 164, 995-1002. 
21. Tomaschitz A, Pilz S, Ritz E et al (2010). Independent association between 1,25-
dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The 
Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 411, 
1354-60. 
22. Forman JP, Williams JS, Fisher ND (2010). Plasma 25-hydroxyvitamin D and 
regulation of the renin-angiotensin system in humans. Hypertension 55, 1283-8. 
23. Pala HG, Ozalp Y, Yener AS et al. (2015). Adiponectin levels in gestational 
diabetes mellitus and in pregnant women without glucose intolerance. Adv Clin Exp 
Med 24, 85-92.  
24.Mohammadi T, Paknahad Z (2017). Adiponectin concentration in gestational 
diabetic women: a case-control study. Clin Nutr Res.  6, 267-276.  
25. Li ZY, Wang P, Miao CY (211). Adipokines in inflammation, insulin resistance and 
cardiovascular disease. Clin Exp Pharmacol Physiol 38, 888-96. 
26. Song Y, Gao J, Qu Y et al (2016). Serum levels of leptin, adiponectin and resistin in 
relation to clinical characteristics in normal pregnancy and preeclampsia. Clin Chim 
Acta 458, 133-7. 
27. Fatima SS, Alam F, Chaudhry B et al (2016). Elevated levels of chemerin, leptin, 
and interleukin-18 in gestational diabetes mellitus. J Matern Fetal Neonatal Med, 1-6. 
28. Menendez C, Lage M, Peino R et al (2001). Retinoic acid and vitamin D(3) 
powerfully inhibit in vitro leptin secretion by human adipose tissue. J Endocrinol 170, 
425-31. 
29. Maetani M, Maskarinec G, Franke AA et al (2009). Association of leptin, 25-
hydroxyvitamin D, and parathyroid hormone in women. Nutr Cancer. 61, 225-31. 
30. Karonova T, Belyaeva O, Jude EB et al (2016). Serum 25(OH)D and adipokines 
levels in people with abdominal obesity. J Steroid Biochem Mol Biol.  
 18 
 
31. Hajimohammadi M, Shab-Bidar S, Neyestani TR (2017). Vitamin D and serum 
leptin: a systematic review and meta-analysis of observational studies and randomized 
controlled trials. Eur J Clin Nutr 71, 1144-53. 
32. Considine RV, Sinha MK, Heiman ML et al (1996). Serum immunoreactive-leptin 
concentrations in normal-weight and obese humans. N Engl J Med 334, 292-5. 
33. Fatima SS, Farooq S, Tauni MA et al (2015). Effect of raised body fat on vitamin D, 
leptin and bone mass. J Pak Med Assoc 65, 1315-9. 
34. Dinca M, Serban MC, Sahebkar A et al (2016). Does vitamin D supplementation 
alter plasma adipokines concentrations? A systematic review and meta-analysis of 
randomized controlled trials. Pharmacol Res 107, 360-71. 
35. Mousa A, Abell SK, Shorakae S et al (2017). Relationship between vitamin D and 
gestational diabetes in overweight or obese pregnant women may be mediated by 
adiponectin. Mol Nutr Food Res 61. 
36. Pratumvinit B, Wongkrajang P, Wataganara T et al (2015). Maternal Vitamin D 
Status and Its Related Factors in Pregnant Women in Bangkok, Thailand. PLoS One 10, 
e0131126. 
37. (US) IoM (2011). Committee to Review Dietary Reference Intakes for  Vitamin D 
and Calcium:   Dietary Reference Intakes for Calcium and Vitamin D. In: Ross AC TC, 
Yaktine AL, Del Valle HB, editors., editor. Washington (DC): National Academies 
Press (US). 
38. Matthews DR, Hosker JP, Rudenski AS et al (1985). Homeostasis model 
assessment: insulin resistance and beta-cell function from fasting plasma glucose and 
insulin concentrations in man. Diabetologia 28, 412-9. 
39. Gordon CC, Chumlea WC, Roche AF (1988). Stature, recumbent length, and 
weight. Anthropometric standardization reference manual Champaign: Human kinetics 
Books. 
40. Statistics. BIoGa (2011). National Household Budget Survey. Nutritional 
composition table of food consumed in Brazil. 
41. Sichieri R, Everhart J (1998). Validity of a Brazilian food frequency questionnaire 
against dietary recalls and estimated energy intake. Nutrition Research 18, 1649-59. 
42. Singer JD, Willett JB (2003). Applied longitudinal data analysis: Modeling change 
and event occurrence: Oxford university press. 
43. Twisk JW (2013). Applied longitudinal data analysis for epidemiology: a practical 
guide: Cambridge University Press. 
 19 
 
44. Greenland S (1983). Tests for interaction in epidemiologic studies: a review and a 
study of power. Stat Med  2, 243-51. 
45. Team RS (2015). RStudio: Integrated Development for R. R Studio, Inc., Boston, 
MA.  
46. Liu NQ, Hewison M (2012). Vitamin D, the placenta and pregnancy. Arch Biochem 
Biophys 523, 37-47. 
47. Figueiredo AC, Cocate PG, Adegboye A et al (2017). Changes in plasma 
concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D during 
pregnancy: a Brazilian cohort. European Journal of Nutrition. 2017. 
48. Schneuer FJ, Roberts CL, Guilbert C et al (2014). Effects of maternal serum 25-
hydroxyvitamin D concentrations in the first trimester on subsequent pregnancy 
outcomes in an Australian population. Am J Clin Nutr 99, 287-95. 
49. Flood-Nichols SK, Tinnemore D, Huang RR et al (2015). Vitamin D deficiency in 
early pregnancy. PLoS One 10, e0123763. 
50. Pereira-Santos M, Queiroz Carvalho G, David Couto R et al (2018). Vitamin D 
deficiency and associated factors among pregnant women of a sunny city in Northeast 
of Brazil. Clin Nutr ESPEN 23, 240-4. 
51. Maeda SS, Borba VZC, Camargo MBR et al (2014). Recommendations of the 
Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and 
treatment of hypovitaminosis D. Arq Bras Endocrinol Metab 58, 411-33. 
52. BRASIL (2013). Programa Nacional de Suplementação de Ferro:manual de 
condutas gerais / Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de 
Atenção Básica,  p. 24. Brasília: Ministério da Saúde. 
53. Jafarzadeh L, Motamedi A, Behradmanesh M et al (2015). A comparison of serum 
levels of 25-hydroxy vitamin d in pregnant women at risk for gestational diabetes 
mellitus and women without risk factors. Mater Sociomed 27, 318-22. 
54. Casey C, McGinty A, Holmes VA, Patterson CC, Young IS, McCance Dr (2018). 
Maternal vitamin D and neonatal anthropometrics and markers of neonatal glycaemia: 
Belfast Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Br J Nutr 120, 
74-80. 
55. Catalano P (2002). The Diabetogenic State of Maternal Metabolism in Pregnancy. 
NewReviews 3, e165–e72. 
 20 
 
56. Catalano PM, Tyzbir ED, Wolfe RR et al (1993). Carbohydrate metabolism during 
pregnancy in control subjects and women with gestational diabetes. Am J Physiol 264, 
E60-7. 
57. Alvarez JA, Ashraf A (2010). Role of vitamin d in insulin secretion and insulin 
sensitivity for glucose homeostasis. Int J Endocrinol 2010, 351385. 
58. Tai K, Need AG, Horowitz M et al (2008). Vitamin D, glucose, insulin, and insulin 
sensitivity. Nutrition 24, 279-85. 
59. Arnold DL, Enquobahrie DA, Qiu C et al (2015). Early pregnancy maternal vitamin 
D concentrations and risk of gestational diabetes mellitus. Paediatr Perinat Epidemiol 
29, 200-10. 
60. Altieri B, Grant WB, Casa SD et al (2016). Vitamin D and pancreas: the role of 
sunshine vitamin in the pathogenesis of Diabetes Mellitus and Pancreatic Cancer. Crit 
Rev Food Sci Nutr, 0. 
61. Gedik O, Akalin S (1986). Effects of vitamin D deficiency and repletion on insulin 
and glucagon secretion in man. Diabetologia  29, 142-5. 
62. Retnakaran R (2017). Adiponectin and β-Cell Adaptation in Pregnancy. Diabetes, 
66, 1121-2. 
63. Qiao L, Wattez JS, Lee S et al (2017). Adiponectin Deficiency Impairs Maternal 
Metabolic Adaptation to Pregnancy in Mice. Diabetes 66, 1126-35. 
64. Butler AE, Cao-Minh L, Galasso R et al (2010) . Adaptive changes in pancreatic 
beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia  53, 
2167-76. 
65. Yuan W, Pan W, Kong J et al (2007). 1,25-dihydroxyvitamin D3 suppresses renin 
gene transcription by blocking the activity of the cyclic AMP response element in the 
renin gene promoter. J Biol Chem 282, 29821-30. 
66. Gannagé-Yared MH, Chedid R, Khalife S et al (2009). Vitamin D in relation to 
metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern 
population. Eur J Endocrinol 160, 965-71. 
67. Nimitphong H, Chanprasertyothin S, Jongjaroenprasert W et al (2009). The 
association between vitamin D status and circulating adiponectin independent of 
adiposity in subjects with abnormal glucose tolerance. Endocrine 36 205-10. 
68. Vaidya A, Williams JS, Forman JP (2012). The independent association between 
25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: 
the NHS and the HPFS. Obesity (Silver Spring) 20, 186-91. 
 21 
 
69. McManus R, Summers K, de Vrijer B et al (2014). Maternal, umbilical arterial and 
umbilical venous 25-hydroxyvitamin D and adipocytokine concentrations in 
pregnancies with and without gestational diabetes. Clin Endocrinol (Oxf) 80, 635-41. 
70. Walsh JM, McGowan CA, Kilbane M et al (2013). The relationship between 
maternal and fetal vitamin D, insulin resistance, and fetal growth. Reprod Sci 20, 536-
41. 
 22 
 
 
 
¹ p-value refers to Mann-Whitney test; ²p-value refers to chi-square test.*Among women with vitamin D sufficiency according to Endocrine Society at baseline, we observed significantly higher proportions of women entering 
pregnancy in the summer and in the autumn, compared with those who became pregnant in the winter. **Among women with vitamin D insufficiency according to Endocrine at baseline, we observed a significantly higher 
proportion of women entering pregnancy in the winter than in the summer. ***Among women with vitamin D insufficiency according to Institute of Medicine at baseline, we observed a significantly higher proportion of women 
entering pregnancy in the winter than in the summer. Abbreviations: 25(OH)D=25-hydroxyvitamin D, IQR: interquartile range; BMI=Body Mass Index. 
  Endocrine Society Guidelines  Institute of Medicine 
 
 
Total 
n=181 
Sufficiency 
25 (OH)D ≥75nmol/L 
n=53 
Insufficiency 
25 (OH)D <75nmol/L 
n=128 
P-value¹ 
Sufficiency 
25 (OH)D ≥50 nmol/L 
n=152 
Insufficiency 
25 (OH)D <50 nmol/L 
n=29 
 
P-value¹ 
Continuous variables Median (IQR) 
25(OH)D (nmol/L) 62.5 (52.5 - 75.0) 82.5 (77.5 - 92.5) 57.5 (50.0 - 65.0) <0.001 67.5 (57.5 - 77.5) 40.0 (37.5 - 45.0) <0.001 
Vitamin D dietary intake (IU/day) 134.2 (84.22 - 185.4) 130.81 (67.89 - 168.5) 136.4 (89.1 - 201.2) 0.127 133.4 (82.7 - 178.9) 135.7 (98.0 - 248.1) 0.193 
Age (y) 26.0 (22.0 - 31.0)  25.5 (21.0 - 31.0) 26.0 (22.0 - 31.0) 0.485  25.0 (21.5 - 31.0) 27.0 (23.0 - 31.0) 0.531 
Early pregnancy BMI (kg/m²) 23.7 (21.9 - 27.0) 23.5 (20.6 - 26.9) 23.7 (22.5 - 27.1) 0.271 23.6 (21.3 - 26.9) 24.8 (22.9 - 28.0) 0.130 
Per-capita family income (USD $) 292.4 (184.8 - 421.0) 301.17 (136.3 - 425.7) 283.6 (193.6 - 417.5) 0.448 277.8 (175.4 - 409.4) 330.4 (208.2 - 438.6) 0.288 
Categorical variables  n (%)                     n (%)       n (%)       P-value²         n (%)       n (%)          P-value² 
Parity      
   
Nulliparous  
70 (38.7)  
34.0 (18) 52 (40.6)  
0.402 
56 (36.8)  14 (48.3)  
0.402 
Primiparous or multiparous 111 (61.3)  66.0 (35) 76 (59.4)  96 (63.2)  15 (51.7)  
Self-reported skin color    
0.788 
   
White  47 (26.0) 26.4 (14) 33 (25.8)  43 (28.3)  4 (13.8)  
0.264 Black 49 (27.1) 30.2 (16) 33 (25.8)  40 (26.3)  9 (31.0)  
Mixed 85 (46.9)  43.4 (23) 62 (48.4)  69 (45.4)  16 (55.2)  
Season b    
<0.001 
  
 
 
Summer  38 (21.0)  18 (34.0) * 20 (15.6)  37 (24.3)  1 (3.5)  
<0.001 
Autumn  47 (26.0)  20 (37.7) * 27 (21.1)  44 (29.0)  3 (10.3)  
Winter  48 (26.5)  5 (9.4)  43 (33.6) ** 33 (21.7)  15 (51.7) * 
Spring 48 (26.5)  10 (18.9)  38 (29.7)  38 (25.0)  10 (34.5)  
Table 1. Baseline characteristics of the study population according to vitamin D sufficiency status in first trimester of pregnancy. 
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Table 2. Markers of glucose and adipokines concentrations of the study population according to vitamin D sufficiency status in first trimester of pregnancy†. 
 
 
¹p-value refers to Mann-Whitney test. Abbreviations: 25(OH)D=25-hydroxyvitamin D; IQR: interquartile range.
 
 
 
 
Endocrine Society Guidelines  
 
Institute of Medicine 
 
 
 
 
Total  
 
 
 
Sufficiency 
25 (OH)D 
≥75nmol/L 
 
 
Insufficiency 
25 (OH)D <75nmol/L 
 
 
Sufficiency 
25 (OH)D ≥50 nmol/L 
 
Insufficiency 
25 (OH)D < 50 
nmol/L 
 
Variables 
 
n  n Median (IQR) n Median (IQR) P-value¹ n Median (IQR) n Median (IQR) P-value 
Glycaemia (mg/dL)             
First trimester 180 83.0 (78.0 - 88.0) 54 79.5 (76.0 - 85.0) 126 84.0 (79.0 - 89.0) 0.003 151 83.0 (78.0 - 87.0) 29 84.0 (79.0 - 95.0) 0.034 
Second trimester 
146 
78.0 (72.0 - 83.0) 
42 
77.5 (70.0 - 82.0) 
104 
78.0 (73.0 - 83.0) 0.204 
122 
77.5 (72.0 - 82.0) 
24 
78.5 (72.0 - 83.5) 0.885 
Third trimester 
149 
79.0 (72.0 - 84.0) 
40 
80.5 (71.5 - 84.5) 
109 
78.0 (72.0 - 84.0) 0.991 
123 
78.0 (71.0 - 84.0) 
26 
80.5 (75.0 - 84.0) 0.346 
Insulin (µU/ml) 
 
 
 
 
 
  
 
 
 
  
First trimester 180 4.34 (2.97 - 6.46) 53 3.37 (2.64 - 6.01) 127 4.58 (3.31 - 6.49) 0.125 152 4.04 (2.90 - 6.31) 28 4.89 (3.28 – 7.71) 0.141 
Second trimester 
149 
4.93 (3.21 - 7.70) 
44 
5.07 (3.26 - 7.53) 
106 
4.92 (3.19 - 7.70) 0.921 
125 
4.90 (3.15 - 7.40) 
24 
6.94 (3.96 - 11.39) 0.082 
Third trimester 
147 
5.75 (3.90 - 8.75) 
40 
6.89 (4.46 - 11.88) 
108 
5.49 (3.71 - 8.26) 0.093 
123 
5.65 (4.08 - 8.28) 
24 
7.63 (3.69 - 11.70) 0.484 
HOMA-IR 
 
 
 
 
 
  
 
 
 
  
First trimester 180 0.86 (0.57 - 1.36) 54 0.65 (0.50 - 1.23) 126 0.93 (0.65 - 1.41) 0.062 152 0.82 (0.56 - 1.30) 28 1.14 (0.80 - 1.73) 0.071 
Second trimester 
144 
0.95 (0.60 - 1.53) 
42 
0.94 (0.59 - 1.41) 
102 
0.96 (0.60 - 1.55) 0.812 
120 
0.95 (0.59 - 1.39) 
24 
1.16 (0.70 - 2.18) 0.106 
Third trimester 
144 
1.12 (0.74 - 1.69) 
38 
1.38 (0.78 - 1.94) 
106 
1.08 (0.70 - 1.65) 0.176 
120 
1.10 (0.74 - 1.57) 
24 
1.60 (0.72 - 2.72) 0.352 
Adiponectin (µg/ml) 
 
 
 
 
 
  
 
 
 
  
First trimester 181 4.96 (3.57 - 7.19) 53 4.49 (3.12 - 6.55) 128 5.26 (3.61 - 7.28) 0.170 152 4.95 (3.52 – 7.08) 29 5.68 (4.07 - 7.91) 0.254 
Second trimester 
146 
5.05 (3.52 - 8.46) 
42 
5.06 (3.65 - 10.91) 
104 
5.04 (3.36 - 7.80) 0.469 
123 
4.75 (3.65 - 10.91) 
23 
6.21 (3.92 - 12.17) 0.123 
Third trimester 
148 
4.59 (3.42 - 6.97) 
41 
4.69 (3.43 - 7.32) 
107 
4.45 (3.32 - 6.91) 0.750 
123 
4.45 (3.32 - 6.63) 
125 
5.21 (3.67 - 7.22) 0.494 
Leptin (ng/dl) 
 
 
 
 
 
  
 
 
 
  
First trimester 181 16.7 (9.9 - 26.2) 54 13.4 (8.3 - 24.2) 127 17.4 (10.8 - 28.0) 0.093 152 16.1 (9.8 – 26.8) 29 17.4 (11.7 – 24.7) 0.588 
Second trimester 
151 
24.8 (16.6 - 41.8) 
44 
20.9 (15.9 - 35.4) 
107 
26.8 (17.3 - 43.2) 0.196 
126 
23.4 (16.2 - 41.8) 
25 
32.7 (19.3 - 40.0) 0.228 
Third trimester 
149 
24.9 (15.9 - 38.8) 
40 
24.1 (14.4 - 38.3) 
109 
25.66 (15.9 - 38.9) 0.472 
124 
23.6 (14.9- 38.1) 
25 
33.3 (25.7 - 47.3) 0.021 
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Table 3. Markers of glucose metabolism and adipokines changes during pregnancy according to vitamin D 
adequacy status¹ at first trimester, Rio de Janeiro, Brazil, 2009-2011. 
 Endocrine society1 Institute of Medicine2 
Fixed-effect β3 95% CI  P-value4 β3 95% CI  P-value4 
Glycaemia (mg/dL)       
Gestational age -0.937 -1.347; -0.526 <0.001 -1.013 -1.405; -0.620 <0.001 
Quadratic gestational age 0.019 0.009; 0.028 <0.001 0.019 0.009; 0.028 <0.001 
Vitamin D sufficiency status 5 3.770 -0.128; 7.667 0.058 3.189 -1.473; 7.851 0.180 
Interaction terms       
Gestational age # vitamin D  status5 -0.109 -0.273; 0.055 0.192 -0.052 -0.245; 0.140 0.593 
Insulin (µU/ml)       
Gestational age  0.167 0.048; 0.287 0.006 0.085 0.017; 0.153 0.014 
Vitamin D sufficiency status 5 2.357 -0.344; 5.058 0.087 1.309 -1.886; 4.503 0.422 
Interaction terms       
Gestational age # vitamin D status5 -0.121 -0.251; 0.009 0.069 -0.024 -0.180; 0.132 0.762 
HOMA-IR       
Gestational age  0.018 -0.005; 0.041 0.116 0.007 -0.007; 0.020 0.320 
Vitamin D sufficiency status 5 0.458 -0.053; 0.970 0.079 0.241 -0.366; 0.848 0.437 
Interaction terms       
Gestational age # vitamin D status5 -0.016 -0.042; 0.010 0.232 0.0002 -0.031; 0.031 0.992 
Adiponectin (µg/ml)       
Gestational age  0.303 0.194; 0.478 <0.001 0.281 0.148; 0.415 <0.001 
Quadratic gestational age  -0.006 -0.009; -0.002 0.001 -0.005 -0.009; -0.002 0.001 
Vitamin D sufficiency status 5 0.737 -0.565; 2.038 0.267 0.991 -0.536; 2.520 0.203 
Interaction terms       
Gestational age # vitamin D status5 -0.070 -0.150; 0.010 0.085 0.008 -0.065; 0.081 0.822 
Leptin (ng/dl)       
Gestational age  1.012 0.430; 1.594 0.001 0.952 0.406; 1.498 0.001 
Quadratic gestational age -0.021 -0.034; -0.007 0.002 -0.020 -0.033; -0.007 0.003 
Vitamin D sufficiency status 5 1.207 -3.580; 5.994 0.621 -4.874 -10.460; 0.712 0.087 
Interaction terms       
Gestational age # vitamin D status5 0.042 -0.211; 0.295 0.745 0.253 -0.044; 0.550 0.095 
1Sufficiency [reference category, 25(OH)D ≥ 75nmol/L]/Inadequacy status [25(OH)D < 75nmol/L]; 2 Sufficiency [reference category, 25(OH)D ≥ 
50nmol/L]/Insufficiency status [25(OH)D < 50nmol/L]; 3β = longitudinal linear regression coefficient; 4p-value  refers to maximum likelihood estimator; 
5The reference category was adequate status of 25(OH)D. Abbreviations: 25(OH)D= 25-hidroxi-vitamin D;  CI = confidence interval. Note: The 
adiponectin, leptin and glycaemia models were adjusted for gestational age and quadratic gestational age in weeks and for women’s age, Body Mass Index 
and seasons (Spring/Summer/Autumn/Winter); the insulin and HOMA-IR models were adjusted for gestational age in weeks and for women’s age, Body 
Mass Index and seasons (Spring/Summer/Autumn/Winter). Glycaemia model: Number of observations = 474; Number of groups = 182; Average of 2.6 
observations per group. Insulin model: Number of observations = 475; Number of groups = 180; Average of 2.6 observations per group. HOMA-IR model: 
Number of observations = 467; Number of groups = 182; Average of 2.6 observations per group. Adiponectin model: Number of observations = 474; 
Number of groups = 182; Average of 2.6 observations per group. Leptin model: Number of observations = 480; Number of groups = 181; Average of 2.7 
observations per group. 
Table 3. Markers of glucose metabolism and adipokines changes during pregnancy according to vitamin D 
sufficiency status in first trimester, Rio de Janeiro, Brazil, 2009-2011. 
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Table 4. Markers of glucose metabolism and adipokines according to vitamin D sufficiency status changes 
during pregnancy, Rio de Janeiro, Brazil, 2009-2011. 
 Endocrine Society¹ Institute of Medicine² 
Fixed-effect β3 95% CI  P-value4 β3 95% CI  P-value4 
Glycaemia (mg/dL)       
Gestational age -0.915 -1.345; -0.484 <0.001 -0.989 -1.369; -0.609 <0.001 
Quadratic gestational age 0.017 0.007; 0.026 0.001 0.018 0.009; 0.027 <0.001 
Vitamin D sufficiency status 5 2.624 -1.244; 6.492 0.184 3.516 -1.317; 8.350 0.154 
Interaction terms       
Gestational age # vitamin D tatus5 -0.049 -0.215; 0.116 0.560 -0.029 -0.260; 0.202 0.805 
Insulin (µU/ml)       
Gestational age  0.107 0.014; 0.201 0.024 0.095 0.029; 0.160 0.004 
Vitamin D sufficiency status 4 0.988 -1.677; 3.654 0.468 2.344 -1.073; 5.760 0.179 
Interaction terms       
Gestational age # vitamin D status5 -0.076 -0.199; 0.047 0.226 -0.153 -0.325; 0.018 0.080 
HOMA-IR       
Gestational age  0.013 -0.006; 0.031 0.178 0.009 -0.004; 0.022 0.178 
Vitamin D sufficiency status 4 0.269 -0.260; 0.797 0.319 0.499 -0.181; 1.178 0.150 
Interaction terms       
Gestational age # vitamin D status5 -0.014 -0.038; 0.011 0.270 -0.030 -0.065; 0.005 0.094 
Adiponectin (µg/ml)       
Gestational age  0.291 0.145; 0.436 <0.001 0.270 0.148; 0.392 <0.001 
Quadratic gestational age  -0.005 -0.008; -0.002 0.003 -0.005 -0.008; -0.002 0.001 
Vitamin D sufficiency status 5 0.847 -0.351; 2.045 0.166 0.186 -1.265; 1.637 0.801 
Interaction terms       
Gestational age # vitamin D status5 -0.056 -0.116; 0.004 0.066 0.006 -0.068; 0.080 0.878 
Leptin (ng/dl)       
Gestational age  1.459 0.829; 2.089 <0.001 1.379 0.814; 1.945 <0.001 
Quadratic gestational age -0.031 -0.045; -0.017 <0.001 -0.030 -0.044; -0.017 <0.001 
Vitamin D sufficiency status 5 1.131 -4.114; 6.376 0.673 -4.046 -10.512; 2.421 0.220 
Interaction terms       
Gestational age # vitamin D status5 0.046 -0.205; 0.297 0.719 0.258 -0.089; 0.604 0.145 
1Sufficiency [reference category, 25(OH)D ≥ 75nmol/L]/ Insufficiency status [25(OH)D < 75nmol/L]; 2 Sufficiency [reference category, 25(OH)D ≥ 
50nmol/L]/ Insufficiency status [25(OH)D < 50nmol/L]; 3β = longitudinal linear regression coefficient; 4p-value  refers to maximum likelihood estimator; 5The 
reference category was adequate status of 25(OH)D. Abbreviations: 25(OH)D= 25-hidroxi-vitamin D;  CI = confidence interval. Note: The adiponectin, 
leptin and glycaemia models were adjusted for gestational age and quadratic gestational age in weeks and for women’s age, Body Mass Index and seasons 
(Spring/Summer/Autumn/Winter); the insulin and HOMA-IR models were adjusted for gestational age in weeks and for women’s age, Body Mass Index and 
seasons (Spring/Summer/Autumn/Winter). Glycaemia model: Number of observations = 503; Number of groups = 207; Average of 2.4 observations per 
group. Insulin model: Number of observations = 509; Number of groups = 205; Average of 2.5 observations per group. HOMA-IR model: Number of 
observations = 498; Number of groups = 207; Average of 2.4 observations per group. Adiponectin model: Number of observations = 506; Number of groups = 
207; Average of 2.4 observations per group. Leptin model: Number of observations = 512; Number of groups = 206; Average of 2.5 observations per group. 
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Figure 1. Changes in glucose metabolism markers and adipokines throughout pregnancy according to 
vitamin D baseline status, Rio de Janeiro/Brazil, 2009-2012. 
A) and B) Glycaemia according to vitamin D status Endocrine Society Practice Guideline and the Institute 
of Medicine cut-off points, respectively; 
C) and D) Insulin according to vitamin D status Endocrine Society Practice Guideline and the Institute of 
Medicine cut-off points, respectively; 
E) and F) HOMA-IR according to vitamin D status Endocrine Society Practice Guideline and the Institute 
of Medicine cut-off points, respectively; 
G) and H) Adiponectin according to vitamin D status Endocrine Society Practice Guideline and the 
Institute of Medicine cut-off points, respectively; 
 
Figure 2. Changes in glucose metabolism markers and adipokines according to vitamin D status throughout 
pregnancy, Rio de Janeiro/Brazil, 2009-2012. 
A) and B) Glycaemia according to vitamin D status Endocrine Society Practice Guideline and the Institute of 
Medicine cut-off points, respectively; 
C) and D) Insulin according to vitamin D status Endocrine Society Practice Guideline and the Institute of 
Medicine cut-off points, respectively; 
E) and F) HOMA-IR according to vitamin D status Endocrine Society Practice Guideline and the Institute of 
Medicine cut-off points, respectively; 
G) and H) Adiponectin according to vitamin D status Endocrine Society Practice Guideline and the Institute 
of Medicine cut-off points, respectively; 
 
